CN109350607B - 包覆魔芋葡甘露聚糖的nadh纳米微球及其制备工艺与应用 - Google Patents
包覆魔芋葡甘露聚糖的nadh纳米微球及其制备工艺与应用 Download PDFInfo
- Publication number
- CN109350607B CN109350607B CN201810718941.7A CN201810718941A CN109350607B CN 109350607 B CN109350607 B CN 109350607B CN 201810718941 A CN201810718941 A CN 201810718941A CN 109350607 B CN109350607 B CN 109350607B
- Authority
- CN
- China
- Prior art keywords
- nadh
- konjac glucomannan
- weight
- nano
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title claims abstract description 94
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 title claims abstract description 77
- 241001312219 Amorphophallus konjac Species 0.000 title claims abstract description 77
- 235000001206 Amorphophallus rivieri Nutrition 0.000 title claims abstract description 77
- 229920002581 Glucomannan Polymers 0.000 title claims abstract description 77
- 229920002752 Konjac Polymers 0.000 title claims abstract description 77
- 229940046240 glucomannan Drugs 0.000 title claims abstract description 77
- 239000000252 konjac Substances 0.000 title claims abstract description 77
- 235000010485 konjac Nutrition 0.000 title claims abstract description 77
- 239000004005 microsphere Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 title abstract description 89
- 239000002077 nanosphere Substances 0.000 claims abstract description 34
- 239000002245 particle Substances 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims description 24
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 21
- 235000010413 sodium alginate Nutrition 0.000 claims description 21
- 239000000661 sodium alginate Substances 0.000 claims description 21
- 229940005550 sodium alginate Drugs 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 17
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000000230 xanthan gum Substances 0.000 claims description 13
- 235000010493 xanthan gum Nutrition 0.000 claims description 13
- 229920001285 xanthan gum Polymers 0.000 claims description 13
- 229940082509 xanthan gum Drugs 0.000 claims description 13
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims description 11
- 235000020956 nicotinamide riboside Nutrition 0.000 claims description 11
- 239000011618 nicotinamide riboside Substances 0.000 claims description 11
- 239000000853 adhesive Substances 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 229950006238 nadide Drugs 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000000080 wetting agent Substances 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- 239000004132 Calcium polyphosphate Substances 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 5
- 235000019827 calcium polyphosphate Nutrition 0.000 claims description 5
- 239000000287 crude extract Substances 0.000 claims description 5
- 230000000593 degrading effect Effects 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 239000000395 magnesium oxide Substances 0.000 claims description 5
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 5
- 235000005152 nicotinamide Nutrition 0.000 claims description 5
- 239000011570 nicotinamide Substances 0.000 claims description 5
- 229960003966 nicotinamide Drugs 0.000 claims description 5
- -1 nicotinamide nucleoside Chemical class 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 5
- 239000002777 nucleoside Substances 0.000 claims description 5
- 235000019750 Crude protein Nutrition 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229930027917 kanamycin Natural products 0.000 claims description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 4
- 229960000318 kanamycin Drugs 0.000 claims description 4
- 229930182823 kanamycin A Natural products 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 3
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 claims description 3
- 229960005305 adenosine Drugs 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- YVBGRQLITPHVOP-UHFFFAOYSA-L disodium;[hydroxy-[hydroxy(oxido)phosphoryl]oxyphosphoryl] hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)(=O)OP(O)([O-])=O YVBGRQLITPHVOP-UHFFFAOYSA-L 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000011534 wash buffer Substances 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 claims description 2
- 241001625930 Luria Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims 5
- 239000007853 buffer solution Substances 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000002131 composite material Substances 0.000 abstract description 6
- 210000004211 gastric acid Anatomy 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 239000002105 nanoparticle Substances 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000007853 structural degeneration Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
时间h | 释放率% |
0 | 0 |
2 | 1.12 |
4 | 20.72 |
6 | 50.24 |
8 | 90.33 |
剩余量 | 0.30 |
总量 | 90.63 |
时间h | 释放率% |
0 | 0 |
2 | 39.57 |
4 | 66.85 |
6 | 85.5 |
8 | 93.27 |
剩余量 | 2.10 |
总量 | 95.37 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810718941.7A CN109350607B (zh) | 2018-07-03 | 2018-07-03 | 包覆魔芋葡甘露聚糖的nadh纳米微球及其制备工艺与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810718941.7A CN109350607B (zh) | 2018-07-03 | 2018-07-03 | 包覆魔芋葡甘露聚糖的nadh纳米微球及其制备工艺与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109350607A CN109350607A (zh) | 2019-02-19 |
CN109350607B true CN109350607B (zh) | 2020-08-28 |
Family
ID=65349633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810718941.7A Active CN109350607B (zh) | 2018-07-03 | 2018-07-03 | 包覆魔芋葡甘露聚糖的nadh纳米微球及其制备工艺与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109350607B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109172545A (zh) * | 2018-10-15 | 2019-01-11 | 泓博元生命科技(深圳)有限公司 | 包覆魔芋葡甘露聚糖的nadh纳米微球及其制备工艺与应用 |
CN109908089A (zh) * | 2019-03-27 | 2019-06-21 | 泓博元生命科技(深圳)有限公司 | 含nadh或nadph的纳米微球及其制备方法与应用 |
CN110179812A (zh) * | 2019-05-17 | 2019-08-30 | 上海交通大学医学院附属瑞金医院 | 一种nad在制备帕金森病药物中的应用 |
CN112618515B (zh) * | 2020-12-29 | 2021-09-24 | 江南大学 | 一种负载外泌体的口服结肠靶向给药的聚合物的制备方法 |
CN112807280B (zh) * | 2021-01-07 | 2023-02-03 | 钇澜杉合成生物技术(北京)有限公司 | 多糖类生物高分子聚合物包覆nmn、nadh的制备工艺及其应用 |
CN113440497B (zh) * | 2021-07-20 | 2022-10-11 | 泓博元生命科技(深圳)有限公司 | 在胃酸中稳定的微囊粉及制备方法和应用 |
CN114836370B (zh) * | 2022-05-23 | 2024-05-10 | 厦门大学 | 一种用于细胞三维培养的壳聚糖微球压片 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104208710A (zh) * | 2014-09-11 | 2014-12-17 | 广西大学 | 一种改性魔芋葡甘露聚糖缓释微囊的制备方法 |
US20170266218A1 (en) * | 2016-03-21 | 2017-09-21 | Steve McNerlin | Nad+ coenzyme formulation and methods of making and using the same |
-
2018
- 2018-07-03 CN CN201810718941.7A patent/CN109350607B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN109350607A (zh) | 2019-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109350607B (zh) | 包覆魔芋葡甘露聚糖的nadh纳米微球及其制备工艺与应用 | |
CN109350611B (zh) | 包覆魔芋葡甘露聚糖的nmn纳米微球及其制备工艺与应用 | |
WO2020113812A1 (zh) | 含nadh的生物高分子纳米球及其制备方法与应用 | |
WO2020113811A1 (zh) | 含烟酰胺单核苷酸的生物高分子纳米球及其制备方法与应用 | |
WO2016145911A1 (zh) | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 | |
WO2016086860A1 (zh) | 一种β-烟酰胺单核苷酸的纯化方法 | |
JP3791552B2 (ja) | 錠剤用賦形剤としてのデンプン製品及びその調製方法及び錠剤の製造方法 | |
Barker et al. | Cross-linked polyacrylamide derivatives (Enzacryls) as water-insoluble carriers of amylolytic enzymes | |
CN1413582A (zh) | 盐酸二甲双胍肠溶片及其制备方法 | |
CN104758307A (zh) | Nadh和nmn在制备帕金森病药物或保健品的应用 | |
CN103239419B (zh) | 茶碱缓释片的制备方法 | |
CN109172545A (zh) | 包覆魔芋葡甘露聚糖的nadh纳米微球及其制备工艺与应用 | |
CN113304177A (zh) | 一种破壁灵芝孢子粉提取物及其崩解片剂的制备方法与应用 | |
CN114366760A (zh) | 海蒿子多酚在制备治疗糖尿病药物中的应用及其制备方法 | |
CN101314034A (zh) | 重组纳豆激酶口服制剂及其制备方法和应用 | |
CN111789861B (zh) | 小分子化合物在抗非洲猪瘟病毒感染中的应用 | |
CN109925287A (zh) | 一种盐酸赛庚啶片剂及其制备方法 | |
TWI590766B (zh) | Thrombotic disease prevention preparation | |
PL92401B1 (zh) | ||
AU2021102578A4 (en) | Biopolymer nanosphere containing nadh, method of preparing the same and use thereof | |
CN103800290B (zh) | 盐酸氨基葡萄糖微丸制剂及其制备方法 | |
CN101410409A (zh) | 免疫调节组合物 | |
AU2021102577A4 (en) | Biopolymer nanosphere containing nicotinamide mononucleotide, preparation method therefor and use thereof | |
WO2001040315A1 (fr) | Alginate a faible poids moleculaire, son procede de preparation et ses applications | |
CN112807280A (zh) | 多糖类生物高分子聚合物包覆nmn、nadh的制备工艺及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190328 Address after: 518000 Shenzhen Bay Science and Technology Eco-Park, Nanshan District, Shenzhen City, Guangdong Province Applicant after: Hongbo Yuan Technology (Shenzhen) limited life Address before: 518000 Room 201, building A, No. 1, Qian Wan Road, Qianhai Shenzhen Hong Kong cooperation zone, Shenzhen, Guangdong (Shenzhen Qianhai business secretary Co., Ltd.) Applicant before: Hongbo Yuan Technology (Shenzhen) limited life Applicant before: Huazhong Agricultural University |
|
TA01 | Transfer of patent application right | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40004885 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |